Vinpocetine pills 5mg №50

Tradename:

Vinpocetine

International unlicensed:

vinpocetine

Dosage Form:

pills

Composition

One pill contains:
Active substance: Vinpocetine - 5 mg.
Excipients: lactose monohydrate - 135 mg, potato starch - 100 mg, aerosil (colloidal silicon dioxide) - 5 mg, talc - 2.5 mg, Magnesium stearate - 2.5 mg.

Description:

round, flat-cylindrical tablets, white or white with a yellowish-white shade of color, with risk and chamfer.
Pharmacotherapeutic group: cerebral blood flow improving agent.

Pharmacological properties:

Pharmacodynamics
It improves brain metabolism, increasing glucose and oxygen consumption by brain tissue. Increases the resistance of neurons to hypoxia, facilitating the transport of oxygen and substrates of energy supply to tissues (due to a decrease in the red blood cell affinity for it, increased absorption and glucose metabolism, switching to an energetically more favorable aerobic direction), selectively blocks Ca2 + / dependent phosphodiesterase (PDE); increases the levels of adenosine-monophosphate (AMP) and cyclic guanosine monophosphate (cGMP) of the brain.
Increases ATP concentration and ATP / AMP ratio in brain tissues; enhances the metabolism of norepinephrine and brain serotonin; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect.
The vasodilating action is associated with a direct relaxing effect on the smooth muscles of the vessels, primarily of the brain. Vinpocetine does not cause the phenomenon of "robbery", primarily enhances the blood supply to the ischemic area of ​​the brain, without changing the blood supply to the intact areas. It improves microcirculation in the brain by reducing platelet aggregation, reducing blood viscosity, increasing red blood cell deformability.
Increases cerebral blood flow; reduces the resistance of cerebral vessels without significantly affecting the systemic circulation (BP, MO, HR).
The therapeutic effect develops approximately 1 week after the start of the drug.
Pharmacokinetics
Absorption: when ingested, it is quickly and completely absorbed into the gastrointestinal tract (mainly in the proximal gastrointestinal tract). Bodosto-stupidity when taken on an empty stomach - about 7%. The maximum concentration in the blood plasma is reached after 1 hour, in the tissues - after 2-4 hours. When passing through the intestinal wall, it is not metabolized. With the introduction of repeated doses of the kinetics is linear.
Distribution: association with plasma proteins - 66%. It penetrates into breast milk (0.25% during the first hour) and through the placental barrier.
Metabolism: clearance - 66.7 l / h exceeds the plasma volume of the liver (50 l / h), which indicates extrahepatic metabolism. The half-life is 3.54-6.12 h.
Withdrawal: excreted by the kidneys and intestines in the ratio 3: 2.

Indications for use

Neurology (as part of complex therapy): as a symptomatic remedy for various forms of cerebral circulatory insufficiency (ishemographer, reconstructive stage of hemorrhagic stroke, consequences of stroke, transient ischemic attack, vascular dementia, vascular fibrosis insufficiency, headache, headache, headache, cardiac insufficiency, headache, ischemic heart failure; ).
Ophthalmology: chronic vascular diseases of the choroid and retina (including occlusion of the central artery or vein of the retina).
Decreased acuity of the perceptual type, Meniere's disease, idiopathic tinnitus.

Contraindications for use

- hypersensitivity to vinpocetine or other components of the drug;
- acute phase of hemorrhagic stroke;
- severe ischemic heart disease, severe cardiac arrhythmias;
- pregnancy and lactation;
- lactose intolerance, lactase deficiency, glucose-galactose malabsorption;
- children's age up to 18 years.
If you have one of these diseases, be sure to consult with your doctor before taking the drug.

Dosing regimen, route of administration and duration of treatment

Inside, after meals, the initial dose is 15 mg / day, the standard daily dose is 5-10 mg 3 times a day. The maximum daily dose is 30 mg. The course of treatment is 1-3 months. Before the abolition of the drug should gradually reduce the dosage.Possible repeated courses 2-3 times a year.

Precautions for use

In the case of initial lengthening of the Q-T interval, as well as simultaneous use with drugs that extend the Q-T interval, periodic ECG monitoring is necessary during the treatment with Vinpocetine.

Symptoms of overdose, measures to assist overdose

Symptoms: increased severity of side effects.
Treatment: gastric lavage, reception of Activated carbon, symptomatic treatment.

Side effect

Cardiovascular: ECG changes (ST segment depression, prolongation of the Q-T interval); tachycardia, extrasystole (cause-and-effect relationship is not established), blood pressure lability (more often decrease).
From the side of the central nervous system: sleep disturbance (insomnia, increased sleepiness); dizziness, headache, general weakness (may be a manifestation of the underlying disease).
Gastrointestinal: dry mouth, nausea, heartburn.
Allergic reactions: skin rash.
Other side effects: increased sweating, hyperemia of the skin.
If any of the side effects indicated in the instruction are aggravated, or you have noticed any other side effects not indicated in the instruction, inform your doctor.

Interaction with other drugs

It is possible to enhance the hypotensive action while applying with methyldopy (requires blood pressure control).
Increases the risk of hemorrhagic complications on the background of Heparin therapy.
Despite the lack of data confirming the possibility of interaction, it is recommended to use caution when used simultaneously with centrally acting drugs, antiarrhythmics and anticoagulants.
Features of the medical use of the drug in pregnant women, women during breastfeeding, children, adults with chronic diseases
During periods of pregnancy and lactation, this drug is contraindicated.
The effect of a medicinal product for medical use on the ability to drive vehicles and mechanisms
During the period of treatment, care must be taken when driving vehicles, machinery, and when engaging in potentially hazardous activities that require increased concentration and psychomotor speed.

Storage conditions

In a dry, dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Shelf life
2 years.
Do not use after the expiration date printed on the package.
Pharmacy sales terms
On prescription.